Trojan condoms contain 'forever chemicals,' lawsuit claims
By Jonathan Stempel
NEW YORK, Sept 9 (Reuters) -A new lawsuit on Monday claims that Trojan condoms are not safe because they contain toxic "forever chemicals," which have been linked to cancer.
In a proposed class action filed in Manhattan federal court, the plaintiff Matthew Goodman said Church & Dwight's CHD.N products, advertised as "America's #1 Condom," are unfit for their intended purpose because they contain per- and polyfluoroalkyl substances, or PFAS.
Goodman said independent lab testing of the Trojan Ultra Thin condoms that he bought at a Manhattan pharmacy found a presence of organic fluorine, which is "practically nonexistent" outside its use in man-made PFAS chemicals.
"Based on the label, he reasonably believed the product was safe for use on his genitalia," the complaint said, referring to Goodman.
"Had defendant disclosed on the label that the products contained PFAS chemicals, and the harms that can result from contact with PFAS chemicals, he would not have purchased the products, or at the very least, would have only been willing to pay significantly less," it added.
The complaint seeks at least $5 million in damages from Ewing, New Jersey-based Church & Dwight for purchasers of Trojan condoms nationwide.
Church & Dwight did not immediately respond to requests for comment after market hours. Lawyers for the plaintiff did not immediately respond to similar requests.
In July, the consumer advocacy blog Mamavation said tests of 29 popular condoms and lubricants found several with a possible presence of PFAS, including Trojan Ultra Thin condoms.
PFAS are found in hundreds of consumer and commercial products including cosmetics, non-stick pans and stain-resistant clothing.
They became known as "forever chemicals" because they do not break down easily in the human body or environment.
PFAS have been linked to negative health effects including higher cholesterol, low birth weights and reduced antibody response to vaccines, as well as kidney and testicular cancer.
The case is Goodman v. Church & Dwight Co, U.S. District Court, Southern District of New York, No. 24-06813.
Reporting by Jonathan Stempel in New York; Editing by Stephen Coates
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
